Literature DB >> 12110584

Tyrosine phosphorylation of Mdm2 by c-Abl: implications for p53 regulation.

Zehavit Goldberg1, Ronit Vogt Sionov, Michael Berger, Yaara Zwang, Ruth Perets, Richard A Van Etten, Moshe Oren, Yoichi Taya, Ygal Haupt.   

Abstract

The p53 tumor suppressor is inhibited and destabilized by Mdm2. However, under stress conditions, this downregulation is relieved, allowing the accumulation of biologically active p53. Recently we showed that c-Abl is important for p53 activation under stress conditions. In response to DNA damage, c-Abl protects p53 by neutralizing the inhibitory effects of Mdm2. In this study we ask whether this neutralization involves a direct interplay between c-Abl and Mdm2, and what is the contribution of the c-Abl kinase activity? We demonstrate that the kinase activity of c-Abl is required for maintaining the basal levels of p53 expression and for achieving maximal accumulation of p53 in response to DNA damage. Importantly, c-Abl binds and phosphorylates Mdm2 in vivo and in vitro. We characterize Hdm2 (human Mdm2) phosphorylation at Tyr394. Substitution of Tyr394 by Phe394 enhances the ability of Mdm2 to promote p53 degradation and to inhibit its transcriptional and apoptotic activities. Our results suggest that phosphorylation of Mdm2 by c-Abl impairs the inhibition of p53 by Mdm2, hence defining a novel mechanism by which c-Abl activates p53.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12110584      PMCID: PMC125401          DOI: 10.1093/emboj/cdf384

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  72 in total

1.  Genotoxic drugs induce interaction of the c-Abl tyrosine kinase and the tumor suppressor protein p53.

Authors:  Z M Yuan; Y Huang; M M Fan; C Sawyers; S Kharbanda; D Kufe
Journal:  J Biol Chem       Date:  1996-10-25       Impact factor: 5.157

Review 2.  The complexity of p53 modulation: emerging patterns from divergent signals.

Authors:  A J Giaccia; M B Kastan
Journal:  Genes Dev       Date:  1998-10-01       Impact factor: 11.361

3.  mdm2 deletion does not alter growth characteristics of p53-deficient embryo fibroblasts.

Authors:  K M McMasters; R Montes de Oca Luna; J R Peña; G Lozano
Journal:  Oncogene       Date:  1996-10-17       Impact factor: 9.867

4.  mdm-2 inhibits the G1 arrest and apoptosis functions of the p53 tumor suppressor protein.

Authors:  J Chen; X Wu; J Lin; A J Levine
Journal:  Mol Cell Biol       Date:  1996-05       Impact factor: 4.272

5.  Role for c-Abl tyrosine kinase in growth arrest response to DNA damage.

Authors:  Z M Yuan; Y Huang; Y Whang; C Sawyers; R Weichselbaum; S Kharbanda; D Kufe
Journal:  Nature       Date:  1996-07-18       Impact factor: 49.962

6.  Nucleo-cytoplasmic shuttling of the hdm2 oncoprotein regulates the levels of the p53 protein via a pathway used by the human immunodeficiency virus rev protein.

Authors:  J Roth; M Dobbelstein; D A Freedman; T Shenk; A J Levine
Journal:  EMBO J       Date:  1998-01-15       Impact factor: 11.598

7.  Activation of the c-Abl tyrosine kinase in the stress response to DNA-damaging agents.

Authors:  S Kharbanda; R Ren; P Pandey; T D Shafman; S M Feller; R R Weichselbaum; D W Kufe
Journal:  Nature       Date:  1995-08-31       Impact factor: 49.962

8.  p53 dependent growth suppression by the c-Abl nuclear tyrosine kinase.

Authors:  A Goga; X Liu; T M Hambuch; K Senechal; E Major; A J Berk; O N Witte; C L Sawyers
Journal:  Oncogene       Date:  1995-08-17       Impact factor: 9.867

9.  The cytostatic function of c-Abl is controlled by multiple nuclear localization signals and requires the p53 and Rb tumor suppressor gene products.

Authors:  S T Wen; P K Jackson; R A Van Etten
Journal:  EMBO J       Date:  1996-04-01       Impact factor: 11.598

10.  Cell type-specific inhibition of p53-mediated apoptosis by mdm2.

Authors:  Y Haupt; Y Barak; M Oren
Journal:  EMBO J       Date:  1996-04-01       Impact factor: 11.598

View more
  60 in total

1.  c-Abl antagonizes the YAP oncogenic function.

Authors:  R Keshet; J Adler; I Ricardo Lax; M Shanzer; Z Porat; N Reuven; Y Shaul
Journal:  Cell Death Differ       Date:  2014-10-31       Impact factor: 15.828

2.  Rewiring kinase specificity with a synthetic adaptor protein.

Authors:  Elissa M Hobert; Alanna Schepartz
Journal:  J Am Chem Soc       Date:  2012-02-22       Impact factor: 15.419

Review 3.  Tied up in loops: positive and negative autoregulation of p53.

Authors:  Xin Lu
Journal:  Cold Spring Harb Perspect Biol       Date:  2009-12-09       Impact factor: 10.005

Review 4.  Role of the nucleus in apoptosis: signaling and execution.

Authors:  Evgeniia A Prokhorova; Alexey V Zamaraev; Gelina S Kopeina; Boris Zhivotovsky; Inna N Lavrik
Journal:  Cell Mol Life Sci       Date:  2015-09-07       Impact factor: 9.261

Review 5.  Dysregulation of ubiquitin ligases in cancer.

Authors:  Jianfei Qi; Ze'ev A Ronai
Journal:  Drug Resist Updat       Date:  2015-09-28       Impact factor: 18.500

6.  MDMX regulation of p53 response to ribosomal stress.

Authors:  Daniele M Gilkes; Lihong Chen; Jiandong Chen
Journal:  EMBO J       Date:  2006-11-16       Impact factor: 11.598

7.  ATM and Chk2-dependent phosphorylation of MDMX contribute to p53 activation after DNA damage.

Authors:  Lihong Chen; Daniele M Gilkes; Yu Pan; William S Lane; Jiandong Chen
Journal:  EMBO J       Date:  2005-09-15       Impact factor: 11.598

Review 8.  Twilight effects of low doses of ionizing radiation on cellular systems: a bird's eye view on current concepts and research.

Authors:  Ilaria Postiglione; Angela Chiaviello; Giuseppe Palumbo
Journal:  Med Oncol       Date:  2009-06-06       Impact factor: 3.064

Review 9.  Probing the mechanisms underlying human diseases in making ribosomes.

Authors:  Katherine I Farley; Susan J Baserga
Journal:  Biochem Soc Trans       Date:  2016-08-15       Impact factor: 5.407

10.  Mechanism of p53 stabilization by ATM after DNA damage.

Authors:  Qian Cheng; Jiandong Chen
Journal:  Cell Cycle       Date:  2010-02-01       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.